Pediatrix Posts 18% EBITDA Jump as Reimbursement Gains Offset Volume Decline
The neonatal and maternal-fetal medicine provider posted $58.2 million in first-quarter adjusted EBITDA, up 18% from a year earlier, while reaffirming its full-year outlook of $280 million to $300 million.
Pediatrix Medical Group (MD) reported first-quarter 2026 adjusted EBITDA of $58.2 million, an 18.2% increase from $49.2 million a year earlier, as reimbursement gains more than offset a continued decline in patient volumes.
The neonatal and maternal-fetal medicine provider posted net revenue of $476.2 million for the quarter ended March 31, up 3.9% from $458.4 million in the year-ago period. Same-unit revenue grew 2.8%, bolstered by a 4.4% increase in net reimbursement-related factors that included improved cash collections, higher hospital contract administrative fees, and elevated patient acuity in neonatology. A slight favorable payor mix shift — commercial and non-government payors rising 45 basis points — added to the top-line tailwind, a dynamic that remained stable despite unfavorable payor mix shifts reported elsewhere in the healthcare sector.
Volume, however, moved in the opposite direction. Same-unit patient volume fell 1.6%, with hospital-based services down 1.5%, office-based services down 3.3%, and NICU days down 0.8%. The decline extended a trend that began in the fourth quarter of 2025, when volumes dropped 2.7% after turning positive in the third quarter of that year. The reimbursement tailwind is also cooling: same-unit reimbursement growth decelerated from 7.6% in the third quarter of 2025 to 6.7% in the fourth quarter and now 4.4% in the first quarter of 2026.
On the bottom line, adjusted earnings per share rose to $0.44 from $0.33 a year ago, while net income per share climbed to $0.36 from $0.24. Both figures declined sequentially from the fourth quarter, reflecting typical first-quarter seasonality; adjusted EBITDA had reached $66 million in the fourth quarter and $87 million in the third quarter of 2025.
Pediatrix reaffirmed its full-year 2026 adjusted EBITDA outlook of $280 million to $300 million, unchanged from its prior guidance. The midpoint would roughly match the $275.6 million the company delivered in full-year 2025, when adjusted EBITDA rose 23% from $224 million in 2024 despite a decline in annual revenue to $1.91 billion from $2.01 billion, a drop tied to practice dispositions. The company's affiliated physician count has continued to shrink, falling to approximately 4,300 as of July 2026 from about 4,400 in August 2025.
Restructuring and transformational expenses fell to $4.9 million from $6.6 million a year earlier, and interest expense declined to $8.3 million from $9.2 million, reflecting lower borrowings and rates. Cash and equivalents stood at $205.8 million at quarter-end, down from $375.2 million at the end of 2025, a drop driven by seasonal first-quarter uses including incentive compensation and benefit plan contributions alongside $21.5 million in share repurchases. Total debt edged down to $591 million from $597 million, with no outstanding borrowings on its $450 million revolving credit facility.
The company continued to buy back stock under a $250 million repurchase program announced in August 2025, purchasing $21.5 million in the first quarter after buying $64 million in the fourth quarter and $20.9 million in the third quarter of 2025. Weighted average diluted shares outstanding fell to 83.1 million from 85.4 million a year ago.